Abstract:The ability to directly trans-differentiate fibroblasts into cardiomyocytes through overexpression of three core transcription factors, Gata4, Mef2C &TBX5 (GMT), has been demonstrated by our group and others. Direct cardiac reprogramming has great potential to treat heart failure. However, clinical application remains limited due to inefficiencies in the reprogramming process and immaturity of the differentiated cardiomyocytes. In the current work, using a chemical approach we aim to increase the efficiency and the maturation of these directly reprogrammed cardiomyocytes. We have optimized a high-throughput screening method in 384-well plates using an alpha-MHC-GFP reporter to detect cardiac reprogramming in mouse cardiac fibroblasts. We screened 5500 compounds and identified 20 hits which have increased the reprogramming efficiency by 2-6 fold compared to controls. Among these top hits, 4 TGF-β inhibitors (DS 1-4) and 4 WNT inhibitors (DS 5-8) enhanced direct cardiac reprogramming. Further in depth investigations showed that the combination of the TGF-β inhibitor DS1 and the WNT inhibitor DS5 increased reprogramming efficiency 7 fold when added to the GMT-overexpressing fibroblasts on the first day of reprogramming. This combination of small molecules also enhanced the maturation of the reprogrammed cells, as we observed beating cells after only 1 week of reprogramming compared to 6–8 weeks without the small molecules. Activation of canonical WNT signaling or TGF-β signaling significantly abrogates the improvement in cardiac reprogramming by DS1 and DS5. These results indicate the specificity of the action of these inhibitors through the canonical WNT and TGF-β pathways. In a translational effort, we injected DS1, 2 and 5 intraperitoneally in mice for 2 weeks in combination with GMT following myocardial infarction (MI) and found a significant improvement in cardiac function as represented by an ejection fraction of 39.11% ±1.2% in the GMT + compounds group vs. 28.44% ± 3.98% in the GMT only group (p<0.05), 6 weeks after MI compared to an ejection fraction of 22.72% in the control untreated group. In conclusion, small molecules, especially the TGF-β inhibitors and WNT inhibitors, greatly enhanced direct reprogramming in vitro and in vivo.

Small Molecules Enable Cardiac Reprogramming of Mouse Fibroblasts with a Single Factor, Oct4.

Regulation of cardiac fibroblasts reprogramming into cardiomyocyte‐like cells with a cocktail of small molecule compounds

Direct reprogramming of mouse fibroblasts into cardiomyocytes with chemical cocktails

In situ reprogramming of cardiac fibroblasts into cardiomyocytes in mouse heart with chemicals

Mouse Cardiomyocytes Generated from Fibroblasts with One Pluripotency Factor and Four Small Molecules

Conversion of Mouse Fibroblasts into Cardiomyocytes Using A Direct Reprogramming Strategy

Reprogramming cell fates by small molecules

Pharmacological Reprogramming of Fibroblasts into Neural Stem Cells by Signaling-Directed Transcriptional Activation

Conversion of Human Fibroblasts into Functional Cardiomyocytes by Small Molecules

Robust Small Molecule-Aided Cardiac Reprogramming Systems Selective to Cardiac Fibroblasts

Brief Report: Combined Chemical Treatment Enables Oct4-Induced Reprogramming from Mouse Embryonic Fibroblasts

Abstract 11415: Enhancing Direct Cardiac Reprogramming Efficiency Using Small Molecules

Small Molecules Facilitate the Reprogramming of Mouse Fibroblasts into Pancreatic Lineages

Lineage Reprogramming Of Fibroblasts Into Expandable Cardiac Progenitor Cells By Defined Small Molecules

Small-Molecule-Driven Direct Reprogramming of Mouse Fibroblasts into Functional Neurons

In Vitro Conversion of Murine Fibroblasts into Cardiomyocyte-Like Cells.

Targeting Mll1 H3K4 Methyltransferase Activity to Guide Cardiac Lineage Specific Reprogramming of Fibroblasts

Reprogramming Fibroblasts Toward Cardiomyocytes, Neural Stem Cells and Hepatocytes by Cell Activation and Signaling-Directed Lineage Conversion

Chemical Enhancement of in Vitro and in Vivo Direct Cardiac Reprogramming.

Abstract 15412: Non-viral Direct Reprogramming of Fibroblasts into a Three Dimensional Vascularized Cardiomimetic Tissue

Direct Cardiac Reprogramming Via Combined CRISPRa-Mediated Endogenous Gata4 Activation and Exogenous Mef2c and Tbx5 Expression